Kiniksa Pharmaceuticals, Ltd.
Stock Forecast, Prediction & Price Target
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock Price Target by analysts
$37.5
Potential upside: 13.63%
Kiniksa Pharmaceuticals, Ltd. price prediction
What is Kiniksa Pharmaceuticals, Ltd. stock analysts` prediction?
Kiniksa Pharmaceuticals, Ltd. stock forecast: Based on 2 Wall Street analysts` predicted price targets for Kiniksa Pharmaceuticals, Ltd. in the last 3 months, the avarage price target is $37.5, with a high forecast of $NaN. The average price target represents a 13.63% change from the last price of $33.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Kiniksa Pharmaceuticals, Ltd. stock Price Target by analysts
Full breakdown of analysts given Kiniksa Pharmaceuticals, Ltd. price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Liisa Bayko Evercore ISI | 0% 0/1 | 10 months ago | $35 6.06% upside | $23.27 | StreetInsider | Previous targets (0) |
Roger Song Jefferies | 0% 0/1 | 12 months ago | $40 21.21% upside | $24.49 | StreetInsider | Previous targets (0) |
Eva Fortea Verdejo Wells Fargo | 0% 0/1 | over 1 year ago | $34 3.03% upside | $19.38 | StreetInsider | Previous targets (0) |
Kiniksa Pharmaceuticals, Ltd. Financial Estimates
Kiniksa Pharmaceuticals, Ltd. Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. EBITDA Estimates
Kiniksa Pharmaceuticals, Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $38.54M N/A | $220.18M 471.24% | $270.25M 22.74% | Avg: $536.39M Low: $529.22M High: $543.55M avg. 98.47% | Avg: $655.24M Low: $629.20M High: $691.61M avg. 22.15% | Avg: $774.14M Low: $743.38M High: $817.11M avg. 18.14% | Avg: $837M Low: $803.74M High: $883.45M avg. 8.11% |
Net Income
% change YoY
| $-157.92M N/A | $183.36M 216.10% | $14.08M -92.31% | Avg: $42.19M Low: $-15.09M High: $82.71M avg. 199.58% | Avg: $48.42M Low: $30.92M High: $57.53M avg. 14.76% | Avg: $98.17M Low: $93.10M High: $105.25M avg. 102.74% | Avg: $62.57M Low: $59.34M High: $67.08M avg. -36.26% |
EBITDA
% change YoY
| $-156.63M N/A | $9.77M 106.23% | $-22.85M -333.85% | Avg: $102.87M Low: $101.50M High: $104.24M avg. 550.12% | Avg: $125.67M Low: $120.67M High: $132.64M avg. 22.15% | Avg: $148.47M Low: $142.57M High: $156.71M avg. 18.14% | Avg: $160.53M Low: $154.15M High: $169.44M avg. 8.11% |
EPS
% change YoY
| -$2.3 N/A | $2.64 214.78% | $0.2 -92.42% | Avg: $0.58 Low: -$0.21 High: $1.15 avg. 192.01% | Avg: $0.64 Low: $0.43 High: $0.8 avg. 9.58% | Avg: $1.37 Low: $1.29 High: $1.46 avg. 113.28% | Avg: $0.87 Low: $0.83 High: $0.93 avg. -36.26% |
Operating Expenses
% change YoY
| $186.08M N/A | $163.44M -12.16% | $238.93M 46.18% | Avg: $552.87M Low: $545.48M High: $560.25M avg. 131.39% | Avg: $675.37M Low: $648.54M High: $712.86M avg. 22.15% | Avg: $797.93M Low: $766.22M High: $842.22M avg. 18.14% | Avg: $862.71M Low: $828.43M High: $910.60M avg. 8.11% |
FAQ
What is Kiniksa Pharmaceuticals, Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 70.20% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -15.09M, average is 42.19M and high is 82.71M.
What is Kiniksa Pharmaceuticals, Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 36.72% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $529.22M, average is $536.39M and high is $543.55M.
What is Kiniksa Pharmaceuticals, Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 69.65% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.21, average is $0.58 and high is $1.15.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Kiniksa Pharmaceuticals, Ltd. stock. The most successful analyst is Liisa Bayko.